Technology
Choose a subcategory:
CALGARY, Alberta, March 10, 2010 ( GLOBE NEWSWIRE)- Liberty Analytics Co., a leading provider of large, small- and micro-cap independent investment research, today initiated coverage on Cerus Corp..
Examples of such risks and uncertainties are: risks relating to the rigorous regulatory requirements required for approval of any drug or drug-device combination products that Discovery Labs may develop, including that: ( a) Discovery Labs
Financial Highlights CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Three months ended Year ended December 31, December 30, ( In thousands of United States dollars, except per share information) 2009 2008 2009 2008 ( Unaudited) Revenues Ne
To read the entire report visit: http:// www.stockpreacher. com/n/ BIEL See what investors are saying about BIEL at penny stock forum StockPreacher. com is a small-cap research and investment commentary provider.
QLT Announces Phase II Clinical Trial Results and Development Plans for the Punctal Plug Delivery Sy
VANCOUVER, British Columbia, March 10, 2010 ( GLOBE NEWSWIRE)-- 90-Day Retention Rate of 81% for Latest Punctal Plug Prototype Device- No Dose Response Seen with Higher Doses in Phase II Clinical Studies- Expand Development Plans of the Pun
The upcoming conferences where Infinity's insights into the Hedgehog pathway and IPI-926 will be discussed include: New York Academy of Sciences " Hedgehog Pathway in Cancer" Symposium- March 17, 2010, New York City- Julian Adams, Ph. D., p
Mutual Agreement Between Japan and Singapore Regarding Tax Assessment Based on Transfer Pricing Taxa
KYOTO, Japan, March 10, 2010 ( GLOBE NEWSWIRE)- Nidec Corporation ( the " Company") today announced that it received a notice from the National Tax Agency of Japan that the relevant taxation authorities of Japan and Singapore reached a mutu
Evotec Reports Good Progress in Product Development in Treatment-Resistant Depression in its Allianc
In particular, the risks and uncertainties include, among other things: risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured; the risk that we will not achieve the anticipated benefits of
Date: March 16, 2010 Time: 9: 30 AM ET Audio Call Dial-In Information: Domestic: 888-462- 6700 International: 970-315- 0485 Passcode: 56696517 Webcast Information: This Webcast can be accessed at Sigma-Aldrich Corporation's web site at http
China Nuokang Bio-Pharmaceutical Inc. is a leading biopharmaceutical company in China focused on the research, development, manufacture, marketing and sales of hematological and cardiovascular products.
Pressure BioSciences, Inc. and Target Discovery, Inc. Announce Product Licensing, Manufacturing, Co-
Such forward looking statements include statements regarding the advantages of PCT in processing tissue samples, including the extraction and recovery of intact functional proteins contained in cellular membranes; that the companies will de
For 2010, Bavarian Nordic maintains its financial expectations with revenues in the level of DKK 475 million, a pre-tax loss in the level of DKK 250 million and net free cash and cash equivalents in the range of DKK 225 to DKK 275 million a